Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03034356|
Recruitment Status : Recruiting
First Posted : January 27, 2017
Last Update Posted : October 7, 2022
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Levetiracetam Drug: Placebo||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia|
|Actual Study Start Date :||September 1, 2018|
|Estimated Primary Completion Date :||September 30, 2023|
|Estimated Study Completion Date :||September 30, 2023|
Experimental: Levetiracetam, Then Placebo
4 weeks of levetiracetam administration (125 mg pill, bid), followed by a 4-week washout, then 4 weeks of placebo pill administration (bid).
Other Name: Keppra
Experimental: Placebo, Then Levetiracetam
4 weeks of placebo administration (bid), followed by a 4-week washout, then 4 weeks of levetiracetam administration (125 mg pill, bid).
Other Name: Keppra
- Neurocognitive function [ Time Frame: 4 weeks ]Cognitive function as measured by the Repeatable Battery for the Assessment of Neurological Status (RBANS)
- Resting-state neuronal response [ Time Frame: 4 weeks ]Neuronal response (measured via functional magnetic resonance imaging, fMRI) in the hippocampus during rest.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03034356
|Contact: Jason R Tregellas, PhD||(303) 315-1086||Jason.Tregellas@va.gov|
|United States, Colorado|
|Rocky Mountain Regional VA Medical Center, Aurora, CO||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Jason R Tregellas, PhD 303-315-1086 Jason.Tregellas@va.gov|
|Principal Investigator: Jason R. Tregellas, PhD|
|Principal Investigator:||Jason R. Tregellas, PhD||Rocky Mountain Regional VA Medical Center, Aurora, CO|